Insider · CIK 0001843665
Christopher Nishan Garabedian
Files at LABP (Landos Biopharma, Inc.). First filing -, latest -.
In brief
Christopher Nishan Garabedian files SEC Form 4 as director at LABP (Landos Biopharma, Inc.). No open-market trade is on file; the transactions below are grants, exercises and other rows that carry no view on the price.
A track record needs three past buys with six months of prices behind them; Christopher Nishan Garabedian has 0, so none is measured yet.
Signals
This insider’s open-market buys and sells, scored.
Transactions
Every row this insider has filed, 3 in all, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| May 23, 2024 | LABP Landos Biopharma, Inc. | DDisposition to issuer Stock Option (right to buy)derivative | -1,800 | - | - | 0 | May 23, 2024 |
| May 23, 2024 | LABP Landos Biopharma, Inc. | DDisposition to issuer Stock Option (right to buy)derivative | -1,800 | - | - | 0 | May 23, 2024 |
| May 23, 2024 | LABP Landos Biopharma, Inc. | DDisposition to issuer Stock Option (right to buy)derivative | -1,800 | - | - | 0 | May 23, 2024 |
Questions about Christopher Nishan Garabedian
Answered from the filings on this page, as of the latest one.
Is Christopher Nishan Garabedian buying or selling?
Christopher Nishan Garabedian has no open-market buy or sell on SEC Form 4; the filings on record are grants, exercises and other transactions.
How did Christopher Nishan Garabedian's past buys perform?
Not measured yet. InsiderTell needs three past buys with six months of prices to publish a track record, and Christopher Nishan Garabedian has 0.
Where does Christopher Nishan Garabedian file Form 4?
Christopher Nishan Garabedian has filed Form 4 at LABP (Landos Biopharma, Inc.). A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.